Every day, the sun rises on Wall Street, and a plethora of professional analysts wake to issue new opinions on stocks. Here at the Fool, we use our "This Just In" column to examine some of these picks-- and the track records of the firm behind them -- so individuals can make better investing decisions.
In addition to following professional banks, anyone can use Motley Fool CAPS to monitor the collective opinions of more than 130,000 members, many of whom demonstrate better investing insight than published analysts do.
Enough top-performing CAPS members have recently turned bullish on Forest Labs
Forest Labs has already picked up a couple of FDA approvals so far this year. With partner Cypress Bioscience, it had the fibromyalgia drug Savella approved in January, to compete with Pfizer's
Like sanofi-aventis
To see what the very best CAPS analysts are saying now about Forest Labs -- and what other winning stocks they're picking -- head on over to CAPS and have a look. Unlike analysts' opinions, which are usually reserved only for paying clients, the community research and resources in CAPS are totally free.
More Foolishness:
- Sometimes being second or third choice isn't so bad.
- Dendreon has taken investors on a wild ride.
- Health care hasn't exactly proven immune to the current market.